A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the long-term, drug-free ...

KIMSHEALTH Cancer Centre successfully treats high-grade B-cell lymphoma patient with CAR T-cell therapy, offering new hope.

Matthew Matasar, MD, discussed what the findings from the ELM-1 trial of odronextamab in diffuse large B-cell lymphoma mean ...

The following is a summary of “Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With ...

Fred Locke, MD, Moffitt Cancer Center, explains why this hematologic cancer is such an attractive target for chimeric antigen ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

A study on the long-term safety of CAR T-cell therapy for B-cell lymphoma patients reveals a favourable safety profile with ...

This cancer-patient dad of three young kids is grateful for a "sci-fi" blood treatment advanced by Vanderbilt and oncologist Dr. Olalekan Oluwole.

Matthew Matasar, MD, discusses odronextamab and the ongoing phase 1 ELM-1 trial in patients with CD20-positive B-cell ...

In 2025, Cellectis will continue to focus its efforts and expenses on advancing its core clinical trials BALLI-01 and NATHALI ...

In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.